On May 30, we said, “Structure Therapeutics (GPCR) isn’t a well-known weight loss treatment stock just yet. But it may soon be. According to JPMorgan, it’s an overlooked player in the weight loss treatment market. The firm has an overweight rating on the stock, with a price target of $65.”
At the time, GPCR traded at about $35. Today, it’s up to $54.29.
All after the company reported promising results from its mid-stage weight loss pill trials.
As noted by Investor’s Business Daily, “The company tested its drug over 12 weeks in patients with obesity but not type 2 diabetes. Patients who took the oral medicine lost 6.9% of their body weight compared to a placebo.”
“Leerink Partners analyst David Risinger says the results compare favorably to Eli Lilly’s oral weight-loss drug, orforglipron. In midstage testing, patients who took the Lilly medicine lost 6.5% of their weight,” they added.